Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Delivery of a monomeric p53 subdomain with mitochondrial targeting signals from pro-apoptotic Bak or Bax.
Pharm Res. 2014 Sep;31(9):2503-15. doi: 10.1007/s11095-014-1346-y. Epub 2014 Mar 15.
Pharm Res. 2014.
PMID: 24633417
Free PMC article.
Re-engineered p53 activates apoptosis in vivo and causes primary tumor regression in a dominant negative breast cancer xenograft model.
Okal A, Matissek KJ, Matissek SJ, Price R, Salama ME, Janát-Amsbury MM, Lim CS.
Okal A, et al.
Gene Ther. 2014 Oct;21(10):903-12. doi: 10.1038/gt.2014.70. Epub 2014 Jul 31.
Gene Ther. 2014.
PMID: 25077773
Free PMC article.
Item in Clipboard
Direct induction of apoptosis using an optimal mitochondrially targeted p53.
Mossalam M, Matissek KJ, Okal A, Constance JE, Lim CS.
Mossalam M, et al. Among authors: okal a.
Mol Pharm. 2012 May 7;9(5):1449-58. doi: 10.1021/mp3000259. Epub 2012 Mar 28.
Mol Pharm. 2012.
PMID: 22380534
Free PMC article.
Item in Clipboard
A single mutant, A276S of p53, turns the switch to apoptosis.
Reaz S, Mossalam M, Okal A, Lim CS.
Reaz S, et al. Among authors: okal a.
Mol Pharm. 2013 Apr 1;10(4):1350-9. doi: 10.1021/mp300598k. Epub 2013 Mar 1.
Mol Pharm. 2013.
PMID: 23402381
Free PMC article.
Item in Clipboard
A chimeric p53 evades mutant p53 transdominant inhibition in cancer cells.
Okal A, Mossalam M, Matissek KJ, Dixon AS, Moos PJ, Lim CS.
Okal A, et al.
Mol Pharm. 2013 Oct 7;10(10):3922-33. doi: 10.1021/mp400379c. Epub 2013 Sep 9.
Mol Pharm. 2013.
PMID: 23964676
Item in Clipboard
The DNA binding domain of p53 is sufficient to trigger a potent apoptotic response at the mitochondria.
Matissek KJ, Mossalam M, Okal A, Lim CS.
Matissek KJ, et al. Among authors: okal a.
Mol Pharm. 2013 Oct 7;10(10):3592-602. doi: 10.1021/mp400380s. Epub 2013 Sep 6.
Mol Pharm. 2013.
PMID: 23968395
Item in Clipboard
Re-engineered p53 chimera with enhanced homo-oligomerization that maintains tumor suppressor activity.
Okal A, Cornillie S, Matissek SJ, Matissek KJ, Cheatham TE 3rd, Lim CS.
Okal A, et al.
Mol Pharm. 2014 Jul 7;11(7):2442-52. doi: 10.1021/mp500202p. Epub 2014 May 29.
Mol Pharm. 2014.
PMID: 24836513
Free PMC article.
Item in Clipboard
Discovery of a Potent and Selective CCR4 Antagonist That Inhibits Treg Trafficking into the Tumor Microenvironment.
Jackson JJ, Ketcham JM, Younai A, Abraham B, Biannic B, Beck HP, Bui MHT, Chian D, Cutler G, Diokno R, Hu DX, Jacobson S, Karbarz E, Kassner PD, Marshall L, McKinnell J, Meleza C, Okal A, Pookot D, Reilly MK, Robles O, Shunatona HP, Talay O, Walker JR, Wadsworth A, Wustrow DJ, Zibinsky M.
Jackson JJ, et al. Among authors: okal a.
J Med Chem. 2019 Jul 11;62(13):6190-6213. doi: 10.1021/acs.jmedchem.9b00506. Epub 2019 Jul 1.
J Med Chem. 2019.
PMID: 31259550
Item in Clipboard
Cite
Cite